These findings suggest that TRIM29 is a promising therapeutic target for overcoming lenvatinib resistance in HCC. CONCLUSION: TRIM29 degrades YBX1 through ubiquitination, thereby …

In summary, TRIM29 aids the aggressiveness of cancer via activation of the oncogenic PI3K/AKT/mTOR pathway. Unraveling how TRIM29 modulates such pathways provides …

In thyroid carcinoma, high expression of TRIM29 activates PI3K/AKT signaling, which circumvents cell cycle arrest at the G0/G1 phase and enhances cancer cell resistance to chemotherapy . …

TRIM29 promotes metastasis in NPC by stimulating PI3K/AKT/mTOR signaling pathway. Since the PI3K/Akt pathway regulates metastasis and is frequently activated in cancer tissues …

Dec 18, 2021 · Mechanistically, circIL4R was regulated by TFAP2C and competitively interacted with miR-761 to enhance the expression of TRIM29, thereby targeting PHLPP1 for ubiquitin …

Feb 6, 2025 · In cancer, TRIM29 exhibits tumor-specific effects, promoting progression in pancreatic and nasopharyngeal cancers via pathways like PI3K/AKT/mTOR and β-catenin, …

Collectively, the results of the present study demonstrated that miR‑122 may exert its tumor suppressive role by targeting TRIM29 and inhibiting the activity of PI3K/AKT signaling. It was …

Mar 10, 2025 · Jiang, T. et al. CircIL4R activates the PI3K/AKT signaling pathway via the miR-761/TRIM29/PHLPP1 axis and promotes proliferation and metastasis in colorectal cancer. …

Mar 1, 2025 · Our study reveals that TRIM29 inhibits the PI3K/AKT signaling pathway by ubiquitinating and degrading YBX1, thereby reversing lenvatinib resistance in HCC. TRIM29 …

Feb 23, 2024 · TRIM29 inhibits PTEN/AKT/mTOR and JAK2/STAT3 signaling pathway in HCC cells. The KEGG enrichment pathways analysis suggested that the effect of TRIM29 in HCC …